KDR and neoplasm: The anti-tumor effect of bevacizumab is primarily attributed to the inhibition of VEGFR2-mediated angiogenesis, thereby slowing the growth of new blood vessels and effectively cutting off the supplement of oxygen and nutrients to the tumor (Ferrara et al., 2004; Garcia et al., 2020; Singh et al., 2020).